A novel electron paramagnetic resonance-based assay for prostaglandin H synthase-1 activity
- PMID: 17007643
- PMCID: PMC1592475
- DOI: 10.1186/1476-9255-3-12
A novel electron paramagnetic resonance-based assay for prostaglandin H synthase-1 activity
Abstract
Background: Prostaglandin H2 synthase (PGHS) is the enzyme that catalyses the two-stage conversion of arachidonic acid to prostaglandin H2 (PGH2) prior to formation of prostanoids that are important in inflammation. PGHS isozymes (-1 and -2) are the target for nonsteroidal anti-inflammatory drugs (NSAIDs). Given the rekindled interest in specific anti-inflammatory PGHS inhibitors with reduced unwanted side effects, it is of paramount importance that there are reliable and efficient techniques to test new inhibitors. Here, we describe a novel in vitro electron paramagnetic resonance (EPR)-based assay for measuring the activity of PGHS-1.
Methods: We validated a novel in vitro PGHS-1 activity assay based on the oxidation of spin-trap agent, 1-hydroxy-3-carboxy-pyrrolidine (CPH) to 3-carboxy-proxy (CP) under the action of the peroxidase element of PGHS-1. This quantifiable spin-adduct, CP, yields a characteristic 3-line electron paramagnetic (EPR) spectrum.
Results: The assay is simple, reproducible and facilitates rapid screening of inhibitors of PGHS-1. Aspirin (100 microM, 1 mM) caused significant inhibition of spin-adduct formation (72 +/- 11 and 100 +/- 16% inhibition of control respectively; P < 0.05). Indomethacin (100 microM) also abolished the signal (114 +/- 10% inhibition of control; P < 0.01). SA and the PGHS-2-selective inhibitor, NS398, failed to significantly inhibit spin-adduct generation (P > 0.05).
Conclusion: We have demonstrated and validated a simple, reproducible, quick and specific assay for detecting PGHS-1 activity and inhibition. The EPR-based assay described represents a novel approach to measuring PGHS activity and provides a viable and competitive alternative to existing assays.
Figures
Similar articles
-
The analysis of nonsteroidal antiinflammatory drug selectivity in prostaglandin G/H synthase (PGHS)-null cells.Inflamm Res. 2001 Jun;50(6):327-32. doi: 10.1007/PL00000252. Inflamm Res. 2001. PMID: 11475335
-
Free radical-dependent inhibition of prostaglandin endoperoxide H Synthase-2 by nitro-arachidonic acid.Free Radic Biol Med. 2019 Nov 20;144:176-182. doi: 10.1016/j.freeradbiomed.2019.03.022. Epub 2019 Mar 25. Free Radic Biol Med. 2019. PMID: 30922958 Review.
-
Differential inhibition of murine prostaglandin synthase-1 and -2 by nonsteroidal anti-inflammatory drugs using exogenous and endogenous sources of arachidonic acid.J Pharmacol Exp Ther. 1997 Feb;280(2):606-13. J Pharmacol Exp Ther. 1997. PMID: 9023270
-
Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2.Ann N Y Acad Sci. 1994 Apr 18;714:136-42. doi: 10.1111/j.1749-6632.1994.tb12037.x. Ann N Y Acad Sci. 1994. PMID: 8017762 Review.
-
PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs.Am J Med. 1993 Aug 9;95(2A):40S-44S. doi: 10.1016/0002-9343(93)90396-7. Am J Med. 1993. PMID: 8357002 Review.
References
-
- Eling TE, Mason RP, Sivarajah K. The formation of aminopyrine cation radical by the peroxidase activity of prostaglandin H synthase and subsequent reactions of the radical. J Biol Chem. 1985;260:1601–1607. - PubMed
-
- Hoffmann C. COX-2 in brain and spinal cord implications for therapeutic use. Curr Med Chem. 2000;7:1113–1120. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
